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ND license.1. Introduction
Recent developments in the chemistry of quinazoline deriva-
tives have given rise to more than ten thousand publications
or patents, and yielded more than one thousand derivatives.
It was stimulated by the pharmaceutical utilization of some
alkaloids possessing the quinazoline skeleton, which are freely
found in nature. Such a natural alkaloid is Febrifugine (known
as Chans-San’s alkaloid), which was used as an antimalarial
agent in 200 years B.C. (Wiseloge, 1963). Most of these com-
pounds have been tested for their pharmacological, herbicidal,
biocidal and other properties. At present, quinazoline deriva-
tives are used in the pharmaceutical industry, in medicine
and in agriculture because of wide variety of activities such
as, antimicrobial (Desai and Desai, 2005), potent anticancer
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Where
(a) Conventional method: ClCH2COCl / THF, ref lux, 2-4 hours
i(b) Conventional method: NH2NH2.H2O / C2H5OH, ref lux, 10-12 hours
i(c) Microwave method: NH2NH2.H2O / C2H5OH, µw,
t = 7.0-8.0 mins at p = 300W.
i(d) Conventional method: Glacial CH3COOH, ref lux, 15-17 hours
i(e) Microwave method:Glacial CH3COOH, µw, t = 9.0-10.0 mins at p 1 = 350W.
R = H (4a, 5a), 3,4,5-trimethoxy (4f , 5f),
4-N(CH3)2 (4b, 5b), 3-OCH3-4-OH (4g, 5g),
4-OH (4c, 5c), 2-Cl (4h, 5h),
4-OCH3 (4d, 5d), 4-Cl (4i, 5i),
3-OC6H5 (4e, 5e), 4-NO2 (4j, 5j).
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388 J.P. Raval et al.(Mani Chandrika et al., 2008), antihistaminic (Alagarsamy
et al., 2008), and CNS activities like analgesic and anti-inﬂam-
matory (Alagarsamy et al., 2003, 2007; Tyagi et al., 1998;
Rather et al., 2010), sedative-hypnotic and anticonvulsant
(Varsha et al., 2008). Furthermore pyrazolyl-quinazoline sys-
tem possesses diverse biological activities such as antimicrobial
(Patel and Barat, 2010), phosphodiesterase inhibitors (Asproni
et al., 2010), antidepressant and anticonvulsant (Sinha and
Sritastava, 1994) activities. This prompted us to synthesize,
using microwave irradiation, a new series of pyrazolyl-oxopro-
pyl-quinazolin-4(3H)-one derivatives, by incorporating the
pyrazolyl moiety at 2nd position of the quinazolinone nucleus.
In continuation with our ongoing research programme on
microwave assisted synthesis of heterocyclic compounds (Raval
and Desai, 2009; Raval et al., 2006, 2008, 2009, 2010), we now
report on the microwave assisted synthesis of 6-bromo-2-(3-(3-
(4-(1-(2-chlorophenyl)-3-methyl-1H-pyrazol-5(4H)-ylideneami no)
phenyl)-5-(substituted phenyl)-4,5-dihydro-1H-pyrazol-1-yl)-
2-oxopropyl)-3-(4-ﬂuorophenyl)quinazolin-4(3H)-one 5a–j
(Scheme 1).
2. Experimental section
General procedure. All the melting points were determined in
PMP-DM scientiﬁc melting point apparatus and are uncor-
rected. The purity of compounds was checked routinely by
TLC (0.5 mm thickness) using silica gel-G coated Al plates
(Merck) and spots were visualized by exposing the dry platesin iodine vapours. The IR spectra (mmax in cm
1) were recorded
on a Shimadzu FT-IR 8300 spectrophotometer using KBr or
Nujol technique, UV spectra (kmax in nm) were recorded on
a Shimadzu UV-160 A (200–400 nm) using DMF as solvent,
1H NMR spectra on a Bruker WM 400FT MHz NMR instru-
ment using DMSO-d6 as solvent and TMS as internal reference
(chemical shifts in d, ppm); 13C NMR were recorded on Varian
AMX 400 (100 MHz) spectrometer as solutions in DMSO-d6
and Mass spectra were recorded on a Jeol JMS D-300 spec-
trometer. The elemental analysis (C, H and N) of compounds
was performed on Carlo Erba-1108 elemental analyzer. The
microwave assisted reactions were carried out in a ‘‘QPro-M
Microwave Synthesis System’’ manufactured by Questron
Technologies Corporation, Ontario L4Z 2E9 (Made in
Canada), where microwaves are generated by magnetron at a
frequency of 2450 MHz having an output energy range of
100–500 W and individual sensor for temperature control
(ﬁbre optic is used as a individual sensor for temperature con-
trol) with attachment of reﬂux condenser with constant stirring
and synthesis on preparative scales (avoids the risk of high
pressure development).
2.1. Chemistry
6-Bromo-2-(3-chloro-2-oxopropyl)-3-(4-ﬂuorophenyl)quinazo-
lin-4(3H)-one 2 was prepared by the reaction of 6-bromo-3-(4-
ﬂuorophenyl)-2-methylquinazolin-4(3H)-one 1 with ClCH2
COCl in dry THF by only conventional method. 6-Bromo-3-
Microwave synthesis, characterization and antimicrobial study 389(4-ﬂuorophenyl)-2-(3-hydrazinyl-2-oxopropyl)quinazolin-4(3
H)-one 3 was prepared by the reaction of 6-bromo-2-(3-chloro-
2-oxopropyl)-3-(4-ﬂuorophenyl)quinazolin-4(3H)-one 2 with
NH2NH2ÆH2O in absolute ethanol by both conventional and
microwave method. 6-Bromo-2-(3-(3-(4-(1-(2-chlorophenyl)-3-
methyl-1H-pyrazol-5(4H)-ylideneamino)phenyl)-5-(substituted
phenyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxopropyl)-3-(4-ﬂuo-
rophenyl)quinazolin-4(3H)-ones 5a–j were prepared by the
reaction of 6-bromo-3-(4-ﬂuorophenyl)-2-(3-hydrazinyl-2-oxo-
pro pyl)quinazolin-4(3H)-one 3 with 1-(4-(1-(2-chlorophenyl)-
3-methyl-1H-pyrazol-5(4H)-ylideneamino)phenyl)-3-(substi-
tuted phenyl)-prop-2-en-1-ones 4a–j in glacial acetic acid by
conventional method and in DMF by microwave method,
respectively. Starting compound 6-bromo-3-(4-ﬂuorophenyl)-
2-methylquinazolin-4(3H)-one 1 was prepared according to
the reported method (Mishra et al., 1997) and compounds 4a–j
were prepared according to the reported procedure (Desai and
Desai, 2007).
2.2. Synthesis of 6-bromo-3-(4-ﬂuorophenyl)-2-methylquinaz-
olin-4(3H)-one 1
Title compound was synthesized according to reported method
(Mishra et al, 1997).
2.3. Conventional synthesis of 6-bromo-2-(3-chloro-2-oxopro-
pyl)-3-(4-ﬂuorophenyl) quinazolin-4(3H)-one 2
To the solution of 6-bromo-3-(4-ﬂuorophenyl)-2-methylqui-
nazolin-4(3H)-one 1 (3.33 g, 0.01 mol) in dry THF (20 mL),
a solution of ClCH2COCl (2.26 mL, 0.02 mol) in dry THF
(10 mL) was added at 0 C dropwise with constant stirring
for 2 h. The reaction mixture was further stirred for 2–4 h at
room temperature and then excess of solvents was distilled
off. The reaction mixture was cooled and poured onto ice-cold
water. The solid that separated in each case was ﬁltered and
recrystallised from ethanol. Yield (3.14 g, 77%) as a white so-
lid, mp 166 C. UV (kmax CH3OH): 238 nm; IR (mmax cm1):
173 (C‚O), 1590 (C‚N), 3060 (ArH), 780 (C–Br), 740
(C–Cl), 1111 (C–F), 2570 (CH2);
1H NMR (400 MHz,
DMSO-d6) d ppm: 8.75–8.30 (m, 7H, Ar-H), 2.30 (s, 2H,
CH2CO), 2.50 (s, 2H, COCH2Cl); MS: m/z 408 [M
+]; Anal.
Calcd for C17H11O2N2ClBrF: C, 49.81; H, 2.68; N, 6.83.
Found: C, 49.83; H, 2.70; N, 6.83%.Table 1 Physical and analytical characterization data of compound
Entry Substituents R Molecular formula Colour
5a H C42H32O2N7ClBrF Dark pinkish powder
5b 4-N(CH3)2 C44H37O2N8ClBrF Yellowish brown solid
5c 4-OH C42H32O3N7ClBrF Dark pink powder
5d 4-OCH3 C43H34O3N7ClBrF Brown powder
5e 3-OC6H5 C48H36O3N7ClBrF Violet powder
5f 3,4,5-(OCH3)3 C45H38O5N7ClBrF Dark brown crystal
5g 3-OCH3-4-OH C43H34O4N7ClBrF Light brown powder
5h 2-Cl C42H31O2N7Cl2BrF Yellow powder
5i 4-Cl C42H31O2N7CI2BrF Pale yellow crystalline pow
5j 4-NO2 C42H31O4N8ClBrF Pink powder2.4. Conventional synthesis of 6-bromo-3-(4-ﬂuorophenyl)-2-(3-
hydrazinyl-2-oxopropyl) quinazolin-4(3H)-one 3
The solution of compound 2 (4.09 g, 0.01 mol) and NH2NH2Æ-
H2O (0.01 mol, 0.9 mL, 99%) in absolute ethanol (15 mL) was
reﬂuxed for 10–12 h in a 250 mL round bottom ﬂask. After the
completion of reaction (monitored using TLC), the excess sol-
vent was then removed by distillation under reduced pressure
and the residue was poured into ice-cold water. The product
that separated was recrystallised from ethanol. Yield (2.01 g,
61%) as a pinkish white powder, mp 196 C. UV (kmax
CH3OH): 234 nm; IR (mmax cm
1): 1710 (C‚O), 1580
(C‚N), 3080 (aromatic C–H), 750 (C–Br), 1113 (C–F), 2570
(CH2), 3440 (NH2), 3380 (NH);
1H NMR (400 MHz,
DMSO-d6) d ppm: 8.70–8.20 (m, 7H, Ar-H), 2.35 (s, 2H,
CH2CO), 5.56 (br, 1H, NH, exchangeable), 4.55 (hump, 2H,
NH2, exchangeable), 2.45 (d, 2H, CH2NH); MS: m/z 405
[M+]; Anal. Calcd for C17H14O2N4BrF: C, 50.37; H, 3.45;
N, 13.82. Found: C, 50.34; H, 3.47; N, 13.84%.
2.5. Microwave mediated synthesis of 6-bromo-3-(4-
ﬂuorophenyl)-2-(3-hydrazinyl-2-oxopropyl) quinazolin-4(3H)-
one 3
The mixture of compound 2 (4.09 g, 0.01 mol) and NH2NH2Æ-
H2O(0.01 mol, 0.9 mL, 99%) in absolute ethanol (15 mL) was
taken in round bottom ﬂask placed in a microwave oven and
irradiated for about 7–8 min (350 W). After the completion
of reaction (monitored using TLC), the excess solvent was then
removed by distillation under reduced pressure and the residue
was poured into ice-cold water. The product that separated
was recrystallised from ethanol. Yield (2.03 g, 83%) as a pink-
ish white crystal.
2.6. Conventional synthesis of 6-bromo-2-[3-{3-[4-{1-(2-
chlorophenyl)-3-methyl-1H-pyrazol-5(4H)-
ylideneamino}phenyl]-5-(substituted phenyl)-4,5-dihydro-1H-
pyrazol-1-yl}-2-oxopropyl]-3-(4-ﬂuorophenyl)quinazolin-
4(3H)-one
Compound 5a. The solution of compound 3 (4.05 g, 0.01 mol)
in glacial acetic acid (20 mL) and 1-(4-(1-(2-chlorophenyl)-3-
methyl-1H-pyrazol-5(4H)-ylideneamino)phenyl)-3-phenyl-prop-
2-en-1-one 4a (4.13 g, 0.01 mol) was reﬂuxed for 16 h. Afters (5a–j).
M.p. (C) kmax in nm
CH3OH
Elemental analysis (%)
Calcd (found)
C H N
192 313 62.96 (62.98) 4.03 (3.97) 12.24 (12.26)
237 291 62.60 (62.03) 4.42 (4.37) 13.27 (13.12)
217 298 61.74 (61.72) 3.95 (4.06) 12.00 (12.03)
247 320 62.14 (62.10) 4.12 (4.11) 11.80 (11.83)
199 300 64.54 (64.56) 4.06 (4.06) 10.98 (10.95)
202 275 60.65 (60.66) 4.30 (4.51) 11.00 (11.04)
250 277 60.97 (60.93) 4.05 (4.16) 11.57 (11.60)
241 335 60.37 (60.37) 3.74 (3.73) 11.73 (11.74)
der 255 298 60.37 (60.33) 3.74 (3.72) 11.73 (11.52)
262 288 59.62 (59.61) 3.69 (3.68) 13.24 (13.21)
Table 2 Spectral data of compounds (5a–j).
Entry IR
cm1 (KBr)
1H NMR d ppm
(400 MHz, DMSO-d6)
13C NMR d ppm
(100 MHz, DMSO-d6)
MS (m/z)
[M+]
5a 1725 (C‚O), 1590 (C‚N), 3060
(aromatic C–H), 745 (C–Cl), 770
(C–Br), 1118 (C–F), 2480 (CH2),
2480, 2960
(aliphatic C–H)
8.60–7.20 (m, 20H, Ar-H),
2.40 (s, 3H, CH3 attached
to pyrazolidene nucleus),
5.80 (d, 2H, 2 · CH2 of
pyrazoline ring), 3.95
(t, 1H, CH of pyrazoline ring),
2.26 (s, 2H, 2 · CH2–CO)
115–135 (aromatic >
C‚C<), 40 (CH3), 49
(2 · CH2 of pyrazoline
ring), 38 (–CH2–), 189
(>C‚O), 172 (aliphatic
>C‚O), 110–140
(heteroaromatics >
C‚N–)
800
5b 1728 (C‚O), 1598 (C‚N), 3052
(aromatic C–H), 748 (C–Cl), 767 (C–Br),
1115 (C–F), 2479 (CH2), 2485, 2957
(aliphatic C–H), 1318 (C–CH3), 1315
[C–N(CH3)2]
7.00–7.95 (m, 19H, Ar-H), 2.38
(s, 3H, CH3 attached to
pyrazolidene nucleus), 5.85
(d, 2H, 2 · CH2 of pyrazoline ring),
3.97 (d, 1H, CH of pyrazoline ring),
2.23 (s, 2H, 2 · CH2–CO), 2.9
[m, 6H, –N(CH3)2)]
113–133 (aromatic >
C‚C<), 42 (CH3),
50 (2 · CH2 of pyrazoline
ring), 40 (-CH2-), 192
(>CO), 170 (aliphatic
>C‚O), 113–143
(heteroaromatics >C‚N-)
842
5c 1721 (C‚O), 1589 (C‚N), 3065
(aromatic C–H), 741 (C–Cl),
772 (C–Br), 1111 (C–F), 2484 (CH2),
2478, 2964 (aliphatic C–H),
1315 (C–CH3), 3572 (C–OH)
6.98–7.93 (m, 19H, Ar-H), 2.42
(s, 3H, CH3 attached to
pyrazolidene nucleus), 5.78
(d, 2H, 2 · CH2 of pyrazoline ring),
3.89 (t, 1H, CH of pyrazoline ring),
2.36 (s, 2H, 2 · CH2–CO), 3.58
(s, 1H, –OH)
114–131 (aromatic >C
‚C<), 43 (CH3), 53
(2 · CH2 of pyrazoline
ring), 37 (–CH2–), 197
(>CO), 171 (aliphatic
>C‚O), 112–141
(heteroaromatics >C‚N–)
815
5d 1730 (C‚O), 1578 (C‚N), 3050
(aromatic C–H), 744 (C–Cl), 780
(C–Br), 1128 (C–F), 2475 (CH2),
2485, 2965 (aliphatic C–H), 1317
(C–CH), 2831 (C–OCH3)
7.20–7.90 (m, 19H, Ar-H), 2.31
(s, 3H, CH3 attached to pyrazolidene
nucleus), 5.72 (d, 2H, 2 · CH2 of
pyrazoline ring), 3.99 (t, 1H, CH of
pyrazoline ring), 2.28 (s, 2H,
2 · CH2–CO), 3.89 (s, 3H, –OCH3)
115–135 (aromatic >
C‚C<), 44 (CH3),
51 (2 · CH2 of pyrazoline
ring), 39 (–CH2–), 199
(>C‚O), 171 (aliphatic
>C‚O), 35.7 (OCH3),
112–145 (heteroaromatics
>C‚N–)
830
5e 1721 (CO), 1593 (C‚N), 3061
(aromatic C–H), 748 (C–Cl), 771
(C–Br), 1113 (C–F), 2473 (CH2),
2467, 2964 (aliphatic C–H), 1310
(C–CH3)
6.85–7.65 (m, 19H, Ar-H), 2.34 (s, 3H,
CH3 attached to pyrazolidene nucleus),
5.86 (d, 2H, CH2 of pyrazoline ring),
3.91 (1, 1H, 2 · CH of pyrazoline ring),
2.37 (s, 2H, 2 · CH2–CO), 6.79–7.77
(m, 5H, –OC6H5)
111–132 (aromatic >C‚
C<), 42 (CH3), 50 (2 ·
CH2 of pyrazoline ring),
39 (–CH2–), 194 (>C‚O),
170 (aliphatic >C‚O),
115–148 (heteroaromatics
>C‚N–)
890
5f 1725 (C‚O), 1591 (C‚N), 3062
(aromatic C–H), 743 (C–Cl), 771 (C–Br),
1112 (C–F), 2483 (CH2), 2481, 2962
(aliphatic C–H) 1313 (C–CH3), 2828
[C–(OCH3)3]
6.99–7.80 (m, 17H, Ar-H), 2.45 (s, 3H,
CH3 attached to pyrazolidene nucleus),
5.89 (d, 2H, 2 · CH2 of pyrazoline ring),
3.87 (t, 1H, CH of pyrazoline ring), 2.31
(s, 2H, 2 · CH2–CO), 3.92 (s, 3H, –OCH3)
110–135 (aromatic >C‚C<),
37 (CH3), 50 (2 · CH2 of
pyrazoline ring), 38.7 (–CH2–),
189 (>C‚O). 171 (aliphatic
>C‚O), 37.5 (3 · OCH3),
110–140 (heteroaromatics >
C‚N–)
888
5g 1728 (C‚O), 1590 (C‚N), 3060
(aromatic C–H), 745 (C–Cl), 770 (C–Br),
1118 (C–F), 2480 (CH2), 2480, 2960
(aliphatic C–H), 1312 (C–CH3), 3566
(C–OH), 2825 (C–OCH3)
6.78–7.86 (m, 18H, Ar-H), 2.48 (s, 3H,
CH3 attached to pyrazolidene nucleus),
5.79 (d, 2H, 2 · CH2 of pyrazoline ring),
3.82 (t, 1H, CH of pyrazoline ring), 2.27
(s, 2H, 2 · CH2–CO), 3.79 (s, 3H, –OCH3),
3.50 (s, 1H, –OH)
112–134 (aromatic >C‚
C<), 44 (CH3), 48 (2 ·
CH2 of pyrazoline ring),
35 (–CH2–), 193 (>C‚O),
169 (aliphatic >C‚O),
113–141 (heteroaromatics
>C‚N–)
843
5h 1726 (C‚O), 1592 (C‚N), 3063
(aromatic C–H), 749 (C–Cl), 775
(C–Br), 1120 (C–F), 2482 (CH2),
2488, 2966 (aliphatic C–H), 1315 (C–CH3)
6.65–7.77 (m, 17H, Ar-H), 2.42 (s, 3H, CH3
attached to pyrazolidene nucleus), 5.88
(d, 2H, 2 · CH2 of pyrazoline ring), 3.96
(t, 1H, CH of pyrazoline ring), 2.22
(s, 2H, 2 · CH2–CO)
114–131 (aromatic >C‚
C<), 41 (CH3), 55 (2 ·
CH2 of pyrazoline ring),
38 (–CH2–), 188 (>C‚O),
175 (aliphatic >C‚O),
118–150 (heteroaromatics
>C‚N–)
833
5i 1730 (CO), 1588 (C‚N), 3058 (aromatic
C–H), 735 (C–Cl), 773 (C–Br), 1120 (C–F),
2481 (CH2),
2482, 2961 (aliphatic C–H), 1314 (C–CH3)
6.72–7.82 (m, 17H, Ar-H), 2.44 (s, 3H,
CH3 attached to pyrazolidene nucleus),
5.90 (d, 2H, 2 · CH2 of pyrazoline ring),
3.92 (t, 1H, CH of pyrazoline ring), 2.33
(s, 2H, 2 · CH2–CO)
114–134 (aromatic >C‚C<),
41(CH3), 49(2 · CH2 of pyrazoline
ring), 36 (–CH2–), 196 (>C‚O),
170 (aliphatic >C‚O), 116–142
(heteroaromatics >C‚N–)
833
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Table 2 (continued)
Entry IR
cm1 (KBr)
1H NMR d ppm
(400 MHz, DMSO-d6)
13C NMR d ppm
(100 MHz, DMSO-d6)
MS (m/z)
[M+]
5j 1728 (C‚O), 1596 (C‚N), 3061 (aromatic
C–H), 749 (C–Cl), 771 (C–Br), 1118 (C–F),
2481 (CH2), 2487, 2967 (aliphatic C–H),
1315 (C–CH3), 1340 (C–NO2)
7.15–7.92 (m, 17H, Ar-H), 2.36 (s, 3H,
CH3 attached to pyrazolidene nucleus),
5.76 (d, 2H, 2 · CH2 of pyrazoline ring),
3.88 (t, 1H, CH of pyrazoline ring), 2.36
(s, 2H, 2 · CH2–CO)
113–133 (aromatic >C‚C<),
43 (CH3), 50 (2 · CH2 of
pyrazoline ring), 37 (–CH2–), 185
(>C‚O), 172 (aliphatic >C‚O),
114–141 (heteroaromatics >C‚N–)
844
Table 3 Comparative study in terms of yield and reaction
period for microwave and conventional techniques for com-
pounds (5a–j).
Entry Microwave methoda Conventional method
Time (min) Temp Yield (%) Time (h) Yield (%)
5a 10.0 116 88 16.0 65
5b 9.0 120 82 15.5 55
5c 9.5 118 80 16.5 60
5d 9.5 118 83 15.0 71
5e 9.0 120 79 17.0 59
5f 10.0 116 86 15.5 49
5g 9.5 118 94 16.0 68
5h 10.0 116 90 16.5 73
5i 10.5 114 82 15.0 54
5j 10.0 118 89 15.5 63
a Power: 350 W.
Microwave synthesis, characterization and antimicrobial study 391the completion of reaction (monitored using TLC), the excess
solvent was then removed by distillation under reduced pres-
sure and the residue was poured into ice-cold water. The prod-
uct that separated was recrystallised from ethanol. Yield
(5.14 g, 65%) as a dark pinkish solid, mp 230 C.
2.7. Microwave mediated synthesis of 6-bromo-2-[3-{3-[4-{1-
(2-chlorophenyl)-3-methyl-1H-pyrazol-5(4H)-
ylideneamino}phenyl]-5-(substituted phenyl)-4,5-dihydro-1H-
pyrazol-1-yl}-2-oxopropyl]-3-(4-ﬂuorophenyl)quinazolin-
4(3H)-one
Compound 5a. A mixture of compound 3 (4.05 g, 0.01 mol) in
glacial acetic acid (20 mL) and 1-(4-(1-(2-chlorophenyl)-3-
methyl-1H-pyrazol-5(4H)-ylideneamino)phenyl)-3-phenyl-prop-
2-en-1-one 4a (4.13 g, 0.01 mol) was taken in 250 mL round
bottom ﬂask placed in a microwave oven and irradiated for
about 8–10 min (350 W). After the completion of reaction
(monitored using TLC), the excess solvent was then removed
by distillation under reduced pressure and the residue was
poured into ice-cold water. The product that separated was
recrystallised from ethanol. Yield (5.15 g, 88%) as a dark pink-
ish powder. Likewise other compounds 5b–j were prepared by
treating 3 with various substituted chalcones.
The Physical, analytical characterization and spectral data
of 5a–j are presented in Tables 1 and 2.
2.8. Antimicrobial activity
The compounds 2, 3 and 5a–j were screened for their antibacte-
rial activity against Bacillus subtilis (ATCC 6633), Staphylococ-
cus aureus (ATCC 6538), Escherichia coli (ATCC 8739) and
Pseudomonas aeruginosa (ATCC 1539) and antifungal activity
against Candida albicans (ATCC 10231) and Candida krusei
(G03) by ﬁlter paper disc technique (GCLMD, 1970; NCCLS,
1997). Standard antibacterial and antifungal drugs Ampicillin,
Amoxicillin, Penicillin and Flucanozole were also tested under
similar conditions for comparison. Results are presented in
Table 4. By visualizing the antimicrobial data it could be ob-
served that some of the compounds possess signiﬁcant activity.
3. Results and discussion
3.1. Characterization
Compound 1 on reaction with chloroacetylchloride yielded 6-
bromo-2-(3-chloro-2-oxopropyl)-3-(4-ﬂuorophenyl)quinazo-
lin-4(3H)-one 2. Among the signiﬁcant feature of 1H NMR
data of 1, the disappearance of singlet at d 2.50 (CH3) and
appearance of two singlets at d 2.30 and d 2.50 due to thechloroacetyl group conﬁrmed the structure. Furthermore,
compound 2 on treatment with hydrazine hydrate gave corre-
sponding 6-bromo-3-(4-ﬂuorophenyl)-2-(3-hydrazinyl-2-oxo-
propyl)quinazolin-4(3H)-one 3. The appearance of bands at
3380 and 3440 cm1 for NH and NH2, respectively in the IR
spectra, and two broad signals at d 4.55 and d 5.56 in 1H
NMR spectra clearly showed the presence of hydrazino group
in compound 3. Further, compound 3 on reﬂuxing with 1-(4-
(1-(2-chlorophenyl)-3-methyl-1H-pyrazol-5(4H)-ylideneamino)
phenyl)-3-(substituted phenyl)-prop-2-en-1-ones 4a–j in the
presence of glacial acetic acid yielded the corresponding 6-bro-
mo-2-(3-(3-(4-(1-(2-chlorophenyl)-3-methyl-1H-pyrazol-5(4H)-
ylideneamino)phenyl)-5-(substituted phenyl)-4,5-dihydro-1H-
pyrazol-1-yl)-2-oxopropyl)-3-(4-ﬂuorophenyl)quinazolin-4(3H)-
one 5a–j (Scheme 1). The structures of compounds 5a–j were
conﬁrmed on the basis of UV, IR, 1H NMR, 13C NMR and
MS spectral data (Table 1 and 2).
The same compounds have been also synthesized using con-
ventional approach and comparative study in terms of yield
and reaction period is shown in Table 3. All the reactions un-
der microwave irradiation were completed within 9.0–10.5 min
with yield (79–94%), whereas similar reactions in boiling eth-
anol under conventional heating (steam bath) gave poor yields
(49–73%) with remarkably longer reaction time periods (15.0–
17.0 h) (Table 3), demonstrating that the effect of microwave
irradiation is not purely thermal. Actually, microwave irradia-
tion facilitates the polarization of the molecules under irradia-
tion causing rapid reaction to occur. This is consistent with the
reaction mechanism, which involves a polar transition state
(Loupy et al, 2001).
Table 4 Antimicrobial activity of compounds (5a–j).
Entry Antibacterial in (lg/mL) Antifungal in (lg/mL)
Gram positive Gram negative
S.a.a ATCC 6538 B.s.b ATCC 6633 E.c.c ATCC 8739 P.a.d ATCC 1539 C.a.e ATCC 10231 C.k.f G03
2 – 22 9 25 10 25
3 15 0.9 8 18 18 22
5a 9 11 22 16 – 20
5b 8 0.8 9 1.1 12 0.8
5c 13 – 16 11 17 9
5d 7 10 13 13 – 12
5e 6 17 0.9 1.8 20 –
5f 11 21 – 19 0.9 20
5g 13 1.1 0.9 – 10 17
5h 15 20 12 12 17 8
5i – 16 – 17 10 0.7
5j 9 10 12 9 7 0.8
Ampicillin 40 45 40 50 – –
Amoxicillin 35 40 38 45 – –
Penicillin 40 38 42 48 – –
Flucanuzole – – – – 40 35
a S.a. – Staphylococcus aureus.
b B.s. – Bacillus subtilis.
c E.c. – Escherichia coli.
d P.a. – Pseudomonas aeruginosa.
e C.a. – Candida albicans.
f C.k. – Candida krusei.
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Antimicrobial results are presented in Table 4. By visualizing
the antimicrobial data it could be observed that some of the
compounds possess signiﬁcant activity. Zone of inhibition
was measured in millimetres. The antifungal activities were
compared to the standard drug Flucanozole (35–40 min), while
Ampicillin (40–50 mm), Amoxicillin (35–45 mm) and Penicillin
(38–48 mm) were used as standard drugs for antibacterial
activity. Compounds 2, 5a, 5f, 5h and 5i showed signiﬁcant
antibacterial activity. Compounds2, 3, 5a, 5e, 5f and 5g showed
moderate to good antifungal activity.
4. Conclusion
A new method for the synthesis of 6-bromo-2-(3-(3-(4-(1-(2-
chlorophenyl)-3-methyl-1H-pyrazol-5(4H)-ylideneamino)phenyl)-
5-(substituted phenyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxopro-
pyl)-3-(4-ﬂuorophenyl)quinazolin-4(3H)-one 5a–j using
microwave irradiation offers signiﬁcant improvement over
existing procedures and thus helps facile entry into a synthesis
of variety of pyrazolylquinazolinone derivatives. Also, this
simple and reproducible technique affords various pyrazolyl-
oxopropyl-quinazolin-4(3H)-one derivatives with short
reaction times, excellent yields, and without formation of
undesirable side products.Acknowledgements
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